Last reviewed · How we verify
Tears Naturale
Tears Naturale is an artificial tear solution that lubricates and moisturizes the ocular surface to relieve dry eye symptoms.
Tears Naturale is an artificial tear solution that lubricates and moisturizes the ocular surface to relieve dry eye symptoms. Used for Dry eye syndrome / Keratoconjunctivitis sicca, Temporary relief of dry eye discomfort and irritation.
At a glance
| Generic name | Tears Naturale |
|---|---|
| Also known as | Tears Naturale® II |
| Sponsor | Andover Research Eye Institute |
| Drug class | Artificial tear / Ocular lubricant |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
This over-the-counter ophthalmic product contains a combination of lubricating agents and demulcents that mimic natural tear composition. It provides temporary relief of dry eye discomfort by coating the cornea and conjunctiva, reducing friction and maintaining moisture on the eye surface.
Approved indications
- Dry eye syndrome / Keratoconjunctivitis sicca
- Temporary relief of dry eye discomfort and irritation
Common side effects
- Transient blurred vision
- Eye irritation
- Allergic reaction (rare)
Key clinical trials
- Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG) (PHASE4)
- A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Subjects With Allergic Conjunctivitis (PHASE4)
- A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis (PHASE4)
- Corneal Thickness Changes in Patient Undergoing Dry Eye Managment (NA)
- A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy (PHASE4)
- Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model (PHASE4)
- Brinzolamide/Brimonidine Combination vs Brimonidine 0.2% in the Prevention of IOP Rise After Nd-YAG Laser Capsulotomy (PHASE4)
- Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tears Naturale CI brief — competitive landscape report
- Tears Naturale updates RSS · CI watch RSS
- Andover Research Eye Institute portfolio CI